Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$43.73 USD

43.73
610,729

+0.56 (1.30%)

Updated May 24, 2024 04:00 PM ET

After-Market: $43.75 +0.01 (0.02%) 4:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for QGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

QIAGEN N.V. [QGEN]

Reports for Purchase

Showing records 181 - 200 ( 236 total )

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 181

03/31/2015

Company Report

Pages: 8

Price: 24.95

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 182

01/29/2015

Company Report

Pages: 9

Final 4Q14 Recap - Lower Estimates Offset By An Interesting Two-Quarter System Sales Growth Trend - FCF Ok - Reaffirm NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 183

01/28/2015

Daily Note

Pages: 9

Pre-Call Summary - 4Q14 Results Mixed - System Sales Strong, But Offset by Weaker HPV - EPS Ok - FCF Stable - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 184

01/23/2015

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 26

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 185

01/22/2015

Company Report

Pages: 8

Expecting 4Q14 Results In Line with Reaffirmation - Enzymatics Tuck-In, Quantiferon Competition - FCF Top of Mind - Maintain NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 186

12/30/2014

Company Report

Pages: 9

Price: 24.95

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 187

10/30/2014

Company Report

Pages: 10

3Q14 Sales & EPS In line - Profiling Tests & Instruments Stand Out - Weaker HPV Offsets Strength - FCF Improving Nicely - PT to $21 - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 188

10/24/2014

Company Report

Pages: 8

3Q14 Preview - Expecting In-line Results - More Optimistic on EU Post Recent Earnings

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 189

09/25/2014

Company Report

Pages: 9

Price: 24.95

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 190

07/31/2014

Company Report

Pages: 10

2Q14 Results Meet Street Expectations - Better Profiling Offset by Challenging Academic & Pharma

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 191

07/27/2014

Industry Report

Pages: 6

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 192

07/27/2014

Industry Report

Pages: 6

The Week Ahead in Life Sciences - Upcoming Events for the Week of July 28

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 193

07/24/2014

Company Report

Pages: 8

2Q14 Preview - Expecting Ok Top-line With EPS Upside from Mix & Opex Leverage

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 194

07/08/2014

Company Report

Pages: 9

Price: 24.95

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 195

05/09/2014

Company Report

Pages: 9

Tweaking EPS Estimates Above Consensus After Model Rebuild

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 196

05/06/2014

Daily Note

Pages: 8

1Q14 Pre-Call Summary - Financials Ok - Guidance Reaffirmed - Another Buyback Announced

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 197

05/06/2014

Daily Note

Pages: 8

1Q14 Pre-Call Summary - Financials Ok - Guidance Reaffirmed

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 198

05/05/2014

Company Report

Pages: 8

Expecting a So-So 1Q14 - Int''l and TB Are Keys to Offsetting Exposure to Weak Hospital Utilization &

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 199

01/30/2014

Company Report

Pages: 8

4Q13 Results a Little Soft - Guidance Seems Doable - Glimmer of Hope for 2014 Upside in Quantiferon Business - PT to $19 - Reaffirming NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 200

01/29/2014

Daily Note

Pages: 9

Pre-conference Call Summary - Soft 4Q13 Results and 2014 Guidance Below Expectations for Sales and EPS - Acquisitions Still Performing Well - Maintain N

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party